A Pilot Phase II Study With BRENTUXIMAB VEDOTIN as Pre-ASCT Induction Therapy in Relapsed/Refractory Hodgkin's Lymphoma Patients Non Responding to IGEV Salvage Treatment
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Aug 2016
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 16 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 14 Aug 2015 According to the ClinicalTrials.gov record, status changed from not yet recruiting to recruiting.
- 23 Sep 2014 New trial record